Marker Therapeutics Inc.

The momentum for this stock is not very good. Marker Therapeutics Inc. is not a good value stock. Marker Therapeutics Inc. is not a good growth stock. Marker Therapeutics Inc. is not very popular among insiders. Marker Therapeutics Inc. is a mediocre stock to choose.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the deve...

News

MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nMRKR stock results show that Marker Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post MRKR...\n more…

Marker Therapeutics Excels in Lymphoma Treatment Study

TipRanks Financial Blog Marker Therapeutics (MRKR) has released an update. Marker Therapeutics has reported promising preliminary results from the Phase 1 APOLLO study of MT-601, showing s...\n more…

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Globe Newswire Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...\n more…

Marker Therapeutics Receives $2M NIH Grant for Lymphoma Study

TipRanks Financial Blog Marker Therapeutics (MRKR) has released an update. Marker Therapeutics has been granted $2 million by the NIH to further its Phase 1 study on MT-601 for patients wi...\n more…

Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study

Seeking Alpha - Healthcare Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study...\n more…

Marker Therapeutics awarded $2M grant from NIH SBIR program

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…